Thursday, 21 Sep 2017

You are here

Herpes Zoster

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ). Given the frequency of HZ in immunocompetent persons and the fact that patients with IMIDs carry at least twice the risk of developing HZ, it is important for rheumatologists to be informed about diagnosis, treatment and most importantly prevention of HZ. We all can recognize the classic vesicular rash of HZ so diagnosis is often made clinically. However, there are cases when the diagnosis is not so clear, including during the prodromal phase, early rash that may resemble HSV infection, contact dermatitis or CA-MRSA, and cases of HZ sine herpete, which occurs ~2% of the time. 

Perhaps the most important reason why rheumatologists should be concerned about HZ is because of the complications, which are numerous and include post-herpetic neuralgia, motor neuropathy, cranial palsy, encephalitis, transverse myelitis and stroke. Numerous groups have recently reported the risk of stroke after HZ, in particular in the first 3 months following infection (Calabrese LH, et al. A&R 2017;69(2):439-46).


As far as treatment, we recommend that all immunocompromised hosts be treated with antivirals (acyclovir, valacyclovir, famciclovir) even if symptoms have been present for > 72 hours, as there is a low ratio of harm-to-benefit and treatment can decrease pain, promote healing and decrease shedding. It remains unclear whether or not antiviral treatment reduces risk of PHN. Complicated HZ (disseminated, CNS, visceral, opthalmic) requires hospital admission and IV antiviral therapy.

In terms of prevention, as Calabrese put it – “the best strategy for preventing complications of HZ is to prevent HZ”. While the live-attenuated herpes zoster vaccine (Zostavax) is contraindicated in the setting of most immunosuppression, the footnotes of the 2017 ACIP recommendations for vaccination state it can be given in the following instances: if not on a biologic, if taking the equivalent of prednisone 20 mg/d or less, or traditional doses if MTX or AZA. Regardless, our Zostavax administration rate remains ~ 5%. There are many reasons for this, including uncertainty of optimal timing, as vaccine efficacy wanes significantly after 5 years. At present time there is a HZ subunit vaccine in the late stages of clinical trials and the data look quite promising as far as duration of immunogenicity and efficacy in older adults (Cunningham AL, NEJM 2016;375:1019-32). Stay tuned.

 

 

Add new comment

More Like This

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.

1 September 2017: The RheumNow Week in Review

This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.